The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker
Abstract
BACKGROUND: The widespread use of prostate‐specific antigen (PSA) screening has had a tremendous impact on all aspects of the management of prostate carcinoma. Although PSA‐based screening has resulted in a stage migration to more organ‐confined tumors at the time of diagnosis, and has been temporally associated with a decrease in prostate carcinoma mortality, PSA screening is imperfect. A recent analysis of results from the Prostate Cancer Prevention Trial (PCPT) has provided insight into the positive predictive value of PSA in the so‐called “normal” range. METHODS: The history of the discovery, initial studies, and subsequent widespread application of PSA screening is reviewed. RESULTS: The application of PSA for screening preceded the development of current prostate biopsy techniques and an upper limit of normal was established without complete disease ascertainment. More recent modifications of PSA‐based screening have been adopted clinically without sufficient validation. With current methods, overdiagnosis of clinically unimportant disease almost certainly occurs and high‐grade, aggressive disease may not be detected sufficiently early to allow successful treatment. CONCLUSIONS: To the authors' knowledge, the optimal upper limit of normal for PSA for prostate carcinoma screening is unknown. New biomarkers of disease are needed; these must be linked with disease prognosis and must be validated in rigorously designed clinical trials. Cancer 2004. © 2004 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Influence of Finasteride on the Development of Prostate Cancer
Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030660 · Cited by 2,518
Self-citationProstate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate
Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., & Redwine, E. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710083171501 · Cited by 2,451
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Self-citationMeasurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A., & Andriole, G. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104253241702 · Cited by 2,361
Sathianathen, N. (2021) · 50 Studies Every Urologist Should Know · doi:10.1093/med/9780190655341.003.0002 · Cited by 2,080
Random Systematic Versus Directed Ultrasound Guided Transrectal Core Biopsies of the Prostate
Hodge, K. K., McNeal, J. E., Terris, M. K., & Stamey, T. A. (1989) · Journal of Urology · doi:10.1016/s0022-5347(17)38664-0 · Cited by 1,571
Oesterling, J. E. (1993) · JAMA · doi:10.1001/jama.270.7.860 · Cited by 1,266
Longitudinal Evaluation of Prostate-Specific Antigen Levels in Men With and Without Prostate Disease
Carter, H. B. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480160073037 · Cited by 1,096
Catalona, W. J. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510080052031 · Cited by 998
Results of Conservative Management of Clinically Localized Prostate Cancer
Chodak, G. W., Thisted, R. A., Gerber, G. S., Johansson, J.-E., Adolfsson, J., Jones, G. W., Chisholm, G. D., Moskovitz, B., Livne, P. M., & Warner, J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300403 · Cited by 928
Cited by
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Protein Glycosylation in Cancer
Stowell, S. R., Ju, T., & Cummings, R. D. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040438 · Cited by 873
Chen, K.-I., Li, B.-R., & Chen, Y.-T. (2011) · Nano Today · doi:10.1016/j.nantod.2011.02.001 · Cited by 645
Decramer, S., de Peredo, A. G., Breuil, B., Mischak, H., Monsarrat, B., Bascands, J.-L., & Schanstra, J. P. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r800001-mcp200 · Cited by 450
Multicolor quantum dots for molecular diagnostics of cancer
Smith, A. M., Dave, S., Nie, S., True, L., & Gao, X. (2006) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.6.2.231 · Cited by 348
Liu, R., Wang, X., Aihara, K., & Chen, L. (2014) · Medicinal Research Reviews · doi:10.1002/med.21293 · Cited by 333
Clinical proteomics: A need to define the field and to begin to set adequate standards
Mischak, H., Apweiler, R., Banks, R. E., Conaway, M., Coon, J., Dominiczak, A., Ehrich, J. H. H., Fliser, D., Girolami, M., Hermjakob, H., et al. (2007) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.200600771 · Cited by 307
PSA and beyond: alternative prostate cancer biomarkers
Saini, S. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0268-6 · Cited by 295
Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer
Husarik, D. B., Miralbell, R., Dubs, M., John, H., Giger, O. T., Gelet, A., Cservenyàk, T., & Hany, T. F. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0552-9 · Cited by 295
Bootstrapping Lasso Estimators
Chatterjee, A., & Lahiri, S. N. (2011) · Journal of the American Statistical Association · doi:10.1198/jasa.2011.tm10159 · Cited by 293
Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancers
Duffy, M. J. (2013) · Medical Principles and Practice · doi:10.1159/000338393 · Cited by 278
A Smart, Autocatalytic, DNAzyme Biocircuit for in Vivo, Amplified, MicroRNA Imaging
Wei, J., Wang, H., Wu, Q., Gong, X., Ma, K., Liu, X., & Wang, F. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201911712 · Cited by 272
Risks and benefits of dietary isoflavones for cancer
Andres, S., Abraham, K., Appel, K. E., & Lampen, A. (2011) · Critical Reviews in Toxicology · doi:10.3109/10408444.2010.541900 · Cited by 168
Blaszczyk, N., Masri, B. A., Mawji, N. R., Ueda, T., McAlinden, G., Duncan, C. P., Bruchovsky, N., Schweikert, H.-U., Schnabel, D., Jones, E. C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0974-3 · Cited by 66
Emerging proteomics biomarkers and prostate cancer burden in Africa
Adeola, H. A., Blackburn, J. M., Rebbeck, T. R., & Zerbini, L. F. (2017) · Oncotarget · doi:10.18632/oncotarget.16568 · Cited by 26
Metadata
- Authors
- Hernández, J., & Thompson, I. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004-08-18
- Volume
- 101
- Issue
- 5
- Pages
- 894-904
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2100531189
- Cited by
- 527
- References
- 67
- FWCI
- 41.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.